World-renowned expert Dan Reinstein (London Vision Clinic, UK) talks about his presentation on a new ICL sizng formula at ESCRS 2019.
Support: No funding was received in the production of this video.
Trending Topic
Trending Topic
Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked
On 28 May 2024, enrolment in phase III clinical trials for sozinibercept in neovascular age-related macular degeneration (nAMD) was completed.1 These trials include two large multicentre, double-masked, randomized controlled trials (RCTs): COAST (OPT-302 with aflibercept in neovascular age-related macular degeneration; ClinicalTrials.gov identifier: NCT04757636) and ShORe (OPT-302 with ranibizumab in neovascular age-related macular degeneration; ClinicalTrials.gov identifier: NCT04757610).2,3 These trials represent one of the largest phase […]
